--- title: "史賽克在從網絡攻擊中恢復的過程中，第二季度的利潤和收入均有所增加" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/294415083.md" description: "史賽克報告第二季度利潤為 12.8 億美元，收入增長至 65.9 億美元，恢復了 3 月份網絡攻擊後的損失。調整後的每股收益為 3.69 美元，超出預期。公司縮小了全年指引，預計調整後的每股收益在 14.95 美元至 15.10 美元之間。儘管財務結果強勁，股價在盤後交易中下跌了 9.5%" datetime: "2026-07-30T20:53:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294415083.md) - [en](https://longbridge.com/en/news/294415083.md) - [zh-HK](https://longbridge.com/zh-HK/news/294415083.md) generator: "portal-rs" --- # 史賽克在從網絡攻擊中恢復的過程中，第二季度的利潤和收入均有所增加 By Elias Schisgall Stryker reported a higher profit and revenue growth in the second quarter as the company recovers from a March cyberattack. The medical technology company on Thursday reported a profit of $1.28 billion, or $3.30 a share, compared with a profit of $884 million, or $2.29 a share, a year earlier. Stripping out certain one-time items, Stryker posted adjusted earnings of $3.69 a share. Analysts surveyed by FactSet were expecting $3.49 a share. Sales rose to $6.59 billion from $6.02 billion, beating analyst expectations for $6.58 billion. MedSurg and Neurotechnology sales rose 9.7%, while the orthopaedics unit reported 9.1% sales growth. Stryker also narrowed its full-year guidance, projecting adjusted earnings of between $14.95 and $15.10 a share, up from a previous low end of $14.90. It expects organic net sales growth between 8.3% and 9.3%, compared with a previous range of 8% to 9.5%. Analysts are expecting full-year adjusted earnings of $14.97 a share. The new sales guidance includes a "modestly positive pricing impact," the company said. Shares of Stryker fell 9.5% to $315.00 in after-hours trading on Thrusday. Chief Executive Kevin Lobo said that company has made "significant progress in our recovery" from the March cyberattack, which disrupted Stryker's Microsoft systems and impacted its first-quarter results. The Wall Street Journal has reported that the hackers behind the attack said they were retaliating against the U.S. on Iran's behalf. "As we have seen in the past, the resilience of our teams when faced with challenges was once again on display," Lobo said. "With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech." Write to Elias Schisgall at elias.schisgall@wsj.com (END) Dow Jones Newswires July 30, 2026 16:46 ET (20:46 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [SYK.US](https://longbridge.com/zh-HK/quote/SYK.US.md) - [FDS.US](https://longbridge.com/zh-HK/quote/FDS.US.md) - [MSFT.US](https://longbridge.com/zh-HK/quote/MSFT.US.md) ## 相關資訊與研究 - [史賽克同意收購旋轉袖增強技術開發商 ZuriMED](https://longbridge.com/zh-HK/news/297556265.md) - [Hollencrest Capital Management 出售了史賽克公司 $SYK 的股票](https://longbridge.com/zh-HK/news/297422828.md) - [史賽克公司內部人士通過新購股採取大膽的新行動](https://longbridge.com/zh-HK/news/297854839.md) - [史賽克公司董事 Mary K. Brainerd 報告購買了價值 4,120.75 美元的普通股](https://longbridge.com/zh-HK/news/297824280.md) - [史賽克｜8-K：2026 財年 Q2 營收 65.89 億美元超過預期](https://longbridge.com/zh-HK/news/294410562.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**